Global Search
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Researchers
Claudia A. Chiriboga, MD

Claudia A. Chiriboga, MD

Researcher
Professor of Neurology and Pediatrics
CUIMC/Harkness Pavilion
180 Fort Washington Avenue
Suite 552
New York, New York, United States

Claudia A. Chiriboga, MD is Professor of Neurology and Pediatrics at CUIMC, and Former Interim Director of the Division of Child Neurology, Departments of Neurology and Pediatrics, Vagelos College of Physicians and Surgeons. She is also Former Chief of Pediatric Neurology at Columbia University’s affiliated hospital, Harlem Hospital Center.

Dr. Chiriboga was born in Peru and educated in Argentina, where she graduated with Honors from the Faculty of Medicine at the National University of Buenos Aires in 1982. She completed training in pediatrics at St. Luke’s-Roosevelt Hospital in 1985. After completing her training in child neurology in 1988 at the Neurological Institute and Babies Hospital of Columbia-Presbyterian Medical Center, Dr. Chiriboga joined the Division of Child Neurology at NewYork-Presbyterian/Columbia University Irving Medical Center. Dr. Chiriboga serves/has served on committees of the NIH, CNS, and ABPN. She is a diplomate of the ABPN in Child Neurology.

Dr. Chiriboga’s current research focuses on Spinal Muscular Atrophy (SMA) clinical trials. Past areas of research, including NIH funding, has focused on congenital infections and neurodevelopmental disorders, including cerebral palsy and effects of perinatal exposures. Her clinical practice focuses on neuromuscular disorders as well as developmental, neurobehavioral neurology, and migraine, and on the treatment of spasticity.

 

Representative Publications:

Onasemnogene Abeparvovec Gene Therapy for Symptomatic Infantile-Onset Spinal Muscular Atrophy in Patients With Two Copies of SMN2 (STR1VE): An Open-Label, Single-Arm, Multicentre, Phase 3 Trial

Treatment of Infantile-Onset Spinal Muscular Atrophy With Nusinersen: Final Report of A Phase 2, Open-Label, Multicentre, Dose-Escalation Study

Psychometric Properties of the PEDI-CAT for Children and Youth With Spinal Muscular Atrophy

Implementation of Population-Based Newborn Screening Reveals Low Incidence of Spinal Muscular Atrophy

Muscle-Specific SMN Reduction Reveals Motor Neuron-Independent Disease in Spinal Muscular Atrophy Models

 

view profile

Related Content

© 2023 rareLife solutions Inc.